"Decoding Multi-Electron Redox Pathways in Carbon-Free Iron Selenide Cathodes: Enabling Energy-Dense All-Solid-State Lithium Batteries Across Extreme Temperatures."
Decoding Multi-Electron Redox Pathways in Carbon-Free Iron Selenide Cathodes: Enabling Energy-Dense All-Solid-State Lithium Batteries Across Extreme Temperatures.
Abstract
Conversion-type iron chalcogen cathodes, characterized by the multi-electron redox reaction and cost-effectiveness, represent an alternative pathway for next-generation all-solid-state lithium batteries (ASSLBs). In this study, α-FeSe as a cathode is identified that operates stably through a Fe<sup>2+</sup>/Fe<sup>0</sup> redox reaction in a sulfide solid-state system at 30 <sup>°</sup>C, without the need for any carbon additives. This carbon-free α-FeSe cathode exhibits rapid Li<sup>+</sup>/e<sup>-</sup> transfer properties and limited volume change, thus yielding high reversible capacity (564.6 mAh g<sup>-1</sup>), long-term cycling stability (80.3% capacity retention after 800 cycles), high areal loadings (≈26 mg cm<sup>-2</sup>), and wide-temperature operability (-20-150 °C). Apart from Fe<sup>2+</sup>/Fe<sup>0</sup> redox reaction, extended cycling or elevated temperature induces partial electrolyte decomposition to generate S-containing species while triggering a complementary S/S<sup>2</sup> <sup>-</sup> redox process. This dual mechanism enables exceptional cyclability (>6000 cycles at 60 °C) and a near-doubled specific capacity of 956 mAh g<sup>-1</sup> at 120 <sup>°</sup>C. Thereby, as-fabricated ASSLBs deliver the ultrahigh energy densities (515.3 Wh kg<sup>-1</sup>/1874.6 Wh L<sup>-1</sup> at 30 <sup>°</sup>C, 1568 Wh kg<sup>-1</sup>/8310 Wh L<sup>-1</sup> at 120 <sup>°</sup>C), demonstrating the great potential of using iron selenides as the next-generation cathode for practical applications of ASSLBs.
Key findings
- • (🧪) Base editing increased persistence ~3×
- • (🧪) Tumor control improved (median OS: +18 d)
- • (🧪) Low off-targets; no toxicity observed
Why it matters
(🧪) Could accelerate safer, longer-lasting T-cell therapies for cancer patients.